Abstract
In recent years new oral anticoagulants have been evaluated in the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, atrial fibrillation to prevent ischemic stroke and in the treatment of acute VTE. While two oral anticoagulants, dabigatran and rivaroxaban, have become available for the prevention of VTE in orthopaedic surgery, other indications still are under evaluation or await approval. There are also areas where these novel drugs have not yet been evaluated. These include patients with acute VTE and cancer, pregnant patients with acute VTE and patient with either rheumatic heart valve disease or artificial heart valves. Finally, in acute care settings, where anticoagulant reversibility is critical, such as during and after coronary artery bypass surgery or acute PCI setting in patients with high bleeding risk, novel intravenous anticoagulant drugs with either short half life or specific antidotes may have added value. This article will focus on these unresolved issues.
Keywords: Thrombosis, new anticoagulants, pregnancy, heart valves, cancer, Anticoagulants, venous thromboembolism, knee arthroplasty, atrial fibrillation, ischemic stroke, dabigatran, rivaroxaban, orthopaedic surgery, rheumatic heart valve disease, artificial heart valves, acute PCI setting, intravenous anticoagulant drugs, coronary artery bypass, tumour, Low-molecular-weight heparin, fondaparinux, hromboprophylaxis, renal dysfunction, creatinine clearance, apixaban, hepatotoxic, hepatic metastases, chemotherapy, Vitamin K antagonists, anti-factor Xa, heparin induced thrombocytopenia, Otamixaban, Eptifibatide in Non-ST, Elevation Acute Coronary Syndrome, myocardial infarction, RB006, antithrombotic prophylaxis, hypercoagulable state
Current Pharmaceutical Design
Title: Further Issues with New Oral Anticoagulants
Volume: 16 Issue: 31
Author(s): M. V. Huisman
Affiliation:
Keywords: Thrombosis, new anticoagulants, pregnancy, heart valves, cancer, Anticoagulants, venous thromboembolism, knee arthroplasty, atrial fibrillation, ischemic stroke, dabigatran, rivaroxaban, orthopaedic surgery, rheumatic heart valve disease, artificial heart valves, acute PCI setting, intravenous anticoagulant drugs, coronary artery bypass, tumour, Low-molecular-weight heparin, fondaparinux, hromboprophylaxis, renal dysfunction, creatinine clearance, apixaban, hepatotoxic, hepatic metastases, chemotherapy, Vitamin K antagonists, anti-factor Xa, heparin induced thrombocytopenia, Otamixaban, Eptifibatide in Non-ST, Elevation Acute Coronary Syndrome, myocardial infarction, RB006, antithrombotic prophylaxis, hypercoagulable state
Abstract: In recent years new oral anticoagulants have been evaluated in the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, atrial fibrillation to prevent ischemic stroke and in the treatment of acute VTE. While two oral anticoagulants, dabigatran and rivaroxaban, have become available for the prevention of VTE in orthopaedic surgery, other indications still are under evaluation or await approval. There are also areas where these novel drugs have not yet been evaluated. These include patients with acute VTE and cancer, pregnant patients with acute VTE and patient with either rheumatic heart valve disease or artificial heart valves. Finally, in acute care settings, where anticoagulant reversibility is critical, such as during and after coronary artery bypass surgery or acute PCI setting in patients with high bleeding risk, novel intravenous anticoagulant drugs with either short half life or specific antidotes may have added value. This article will focus on these unresolved issues.
Export Options
About this article
Cite this article as:
V. Huisman M., Further Issues with New Oral Anticoagulants, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563356
DOI https://dx.doi.org/10.2174/138161210793563356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants
Current Clinical Pharmacology Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology Arterial Duct Stenting in Congenital Heart Disease with Duct-Dependent Pulmonary Circulation
Current Pediatric Reviews Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women
Current Vascular Pharmacology Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Vaccines and Photodynamic Therapies for Oral Microbial-Related Diseases
Current Drug Metabolism Engineered Polymeric Biomaterials for Tissue Engineering
Current Tissue Engineering (Discontinued) Naoxintong Protects against Atherosclerosis through Lipid-lowering and Inhibiting Maturation of Dendritic Cells in LDL Receptor Knockout Mice fed a High-fat Diet
Current Pharmaceutical Design Jean-Baptiste de Sénac’s (1693-1770) Important Work on Cardiology and Valvular Disorders
Current Pharmaceutical Design Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Novel Strategies for Combating Pathogenic Biofilms Using Plant Products and Microbial Antibiosis
Current Pharmaceutical Biotechnology Microfluidic Devices for Circulating Tumor Cells Isolation and Subsequent Analysis
Current Pharmaceutical Biotechnology